- Home
- TNYA vs IPSC Comparison
TNYA vs IPSC Comparison
Compare TNYA & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNYA
- IPSC
- Stock Information
- Founded
- TNYA 2016
- IPSC 2019
- Country
- TNYA United States
- IPSC United States
- Employees
- TNYA N/A
- IPSC 165
- Industry
- TNYA Medicinal Chemicals and Botanical Products
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- TNYA Health Care
- IPSC Health Care
- Exchange
- TNYA Nasdaq
- IPSC Nasdaq
- Market Cap
- TNYA 74.7M
- IPSC 62.1M
- IPO Year
- TNYA 2021
- IPSC 2021
- Fundamental
- Price
- TNYA $1.11
- IPSC $0.73
- Analyst Decision
- TNYA Strong Buy
- IPSC Strong Buy
- Analyst Count
- TNYA 5
- IPSC 5
- Target Price
- TNYA $17.50
- IPSC $11.00
- AVG Volume (30 Days)
- TNYA 1.9M
- IPSC 488.9K
- Earning Date
- TNYA 03-17-2025
- IPSC 03-13-2025
- Dividend Yield
- TNYA N/A
- IPSC N/A
- EPS Growth
- TNYA N/A
- IPSC N/A
- EPS
- TNYA N/A
- IPSC N/A
- Revenue
- TNYA N/A
- IPSC $2,684,000.00
- Revenue This Year
- TNYA N/A
- IPSC $230.60
- Revenue Next Year
- TNYA N/A
- IPSC $31.83
- P/E Ratio
- TNYA N/A
- IPSC N/A
- Revenue Growth
- TNYA N/A
- IPSC 7.88
- 52 Week Low
- TNYA $0.86
- IPSC $0.68
- 52 Week High
- TNYA $7.01
- IPSC $5.51
- Technical
- Relative Strength Index (RSI)
- TNYA 44.41
- IPSC 30.98
- Support Level
- TNYA $1.43
- IPSC $0.72
- Resistance Level
- TNYA $1.12
- IPSC $0.82
- Average True Range (ATR)
- TNYA 0.10
- IPSC 0.06
- MACD
- TNYA 0.05
- IPSC 0.01
- Stochastic Oscillator
- TNYA 65.70
- IPSC 27.43
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.